Investors & Media

Aug 10, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Aug 10, 2022 / Aug 10, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

8/10/22

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 - - Ended second quarter 2022 with...
Read More
7/18/22

BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec --(BUSINESS WIRE)--Jul. 18, 2022-- BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common shares at...
Read More
7/13/22

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
Common Shares Priced at US$9.25 per Share LAVAL, Quebec --(BUSINESS WIRE)--Jul. 13, 2022-- In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today...
Read More